Medical/Pharmaceuticals
Sinocare Showcases Its Comprehensive Diabetes Management Solutions at EASD
VIENNA, Oct. 15, 2025 /PRNewswire/ -- The 61st Annual Meeting of the European Association for the Study of Diabetes (EASD 2025) was successfully held in Vienna, Austria. During the conference, Sinocare hosted an international industry symposium and an exclusive networking dinner, fully demonstrati...
2025-10-15 14:34
1210
Safex Chemicals India Ltd. Receives Frost & Sullivan's 2025 Global Competitive Strategy Leadership Recognition for Excellence in Crop Protection Chemicals
Safex earns global recognition for its innovation-driven strategy, digital
transformation, and customer-centric approach in the evolving crop protection
chemicals industry.
SAN ANTONIO, Oct. 15, 2025 /PRNewswire/ -- Frost & Sullivan
2025-10-15 14:00
1032
At the World Congress of Neurology, WHO Outlines a Global Roadmap to Make Brain Health a Universal Reality
SEOUL, South Korea and LONDON, Oct. 15, 2025 /PRNewswire/ -- Neurological conditions now affect more than 40% of the population—over 3 billion people, according to WHO's Global Status Report on Neurology, released at the World Congress of Neurology (WCN) inSeoul. The report reveals that neurolog...
2025-10-15 13:32
958
Pictor's Proteomics Platform Offers Promising Advancement for Detecting Mycoplasma bovis in Cattle
New research highlights the Pictor PictVet™ Mycoplasma bovis IgG Multiplex ELISA's enhanced analytical performance through multiplexing and its potential to enhance global disease management. CARLSBAD, Calif., Oct. 14, 2025 /PRNewswire/ -- Mycoplasma bovis is a devastating pathogen that threate...
2025-10-14 21:00
903
India's No:1 Ranked Institute IIT Madras partners with Hyundai Motor India to launch 'Hyundai Hope for Cancer' to revolutionize Paediatric Cancer Care
CHENNAI, India, Oct. 14, 2025 /PRNewswire/ -- Indian Institute of Technology Madras (IIT Madras),India's No:1 Ranked Educational Institution, is partnering with Hyundai Motor India Foundation (HMIF), the CSR arm of Hyundai Motor India Limited (HMIL), to launch 'Hyundai Hope for Cancer' - a pionee...
2025-10-14 20:30
1023
Infosys Chosen by NHSBSA to Deliver a New Workforce Management Solution for the NHS in England and Wales
Next-Generation solution supports the NHS 10-year Health Plan and the mission
to create a workforce that is fit for the future
LONDON and BENGALURU, India, Oct. 14, 2025 /PRNewswire/ -- Infosys
2025-10-14 18:02
1009
Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration
- Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulgaris compared with placebo in a Phase III randomized, double-blind, placebo-controlled, multicenter clinical trial. HONG KONG, Oct. 14, 2025...
2025-10-14 18:00
1294
Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded
MELBOURNE, Australia and INDIANAPOLIS, Oct. 14, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today provides an update on its commercial and operational performance for the quarter ended30 September 2025 (Q3 2025). All figures are in USD unless stated otherwi...
2025-10-14 14:59
1408
Great Novel Therapeutics Biotech & Medicals Corporation (GNTbm) Presented Preclinical Data on GNTbm-TKI, a Novel Multi-tyrosine Kinase Inhibitor with Potent Immune Activation, at the 2025 ESMO Annual Meeting
TAIPEI, Oct. 14, 2025 /PRNewswire/ -- GNTbm (stock code: 7427, Taiwan) announced the preclinical data on GNTbm-TKI, a novel multi-receptor tyrosine kinase inhibitor for cancer immunotherapy. GNTbm-TKI will be presented as posters at the 2025European Society for Medical Oncology (ESMO) Annual Meet...
2025-10-14 14:26
916
2025 ACR Abstract Released! Exciting Data from Telitacicept's Phase III Clinical Study in Sjögren's Syndrome in China
* In the results of China Phase III clinical trial announced at the 2025 ACR, Telitacicept demonstrated statistically significant and clinically meaningful improvements in ESSDAI [EULAR (European League Against Rheumatism) Sjögren's Syndrome Disease Activity Index] compared to placebo. * Teli...
2025-10-14 13:44
491
Everest Medicines Announces First Patient Enrolled in a Global Multi-Center Phase I Clinical Trial of Tumor-Associated Antigen Cancer Vaccine EVM14
SHANGHAI, Oct. 14, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that the first patient has been enro...
2025-10-14 12:13
1182
Waters Launches Charge Detection Mass Spectrometry Technology to Accelerate the Development of Next-Generation Biotherapeutics
Headlines: * Xevo™ CDMS facilitates direct, accurate mass detection for the largest, most heterogeneous biomolecules.1 * Enables accurate analysis of protein complexes, nucleic acids, and gene delivery vehicles, including distinguishing between empty, partial, full, and overfull viral vector...
2025-10-13 20:36
1306
Chiron Medical Launches "Early Check, Early Hope" Campaign, Embracing Pink for Breast Cancer Awareness
HONG KONG, Oct. 13, 2025 /PRNewswire/ -- According to government statistics[1], breast cancer ranks as the third leading cause of cancer deaths among women in Hong Kong, with an average of one in every 14 women likely to be diagnosed with the disease in their lifetime. The medical community widely...
2025-10-13 19:46
1035
LTS expands its CDMO capabilities with the acquisition of Renaissance Lakewood
ANDERNACH, Germany, Oct. 13, 2025 /PRNewswire/ -- LTS LOHMANN Therapie-Systeme AG ("LTS"), a leading pharmaceutical technology company today announces the acquisition of Renaissance Lakewood, LLC ("Renaissance"), a US-based contract development and manufacturing organization (CDMO) specializing i...
2025-10-13 18:00
1157
AnnJi Showcases Clinical Breakthrough of AJ201 at WMS 2025
TAIPEI, Oct. 13, 2025 /PRNewswire/ -- AnnJi Pharmaceutical Co., Ltd. (AnnJi, TWSE: 7754) announced that the Phase 2a clinical result of AJ201 for spinal and bulbar muscular atrophy (SBMA, also known as Kennedy's disease) was selected as one of the seven Late-Breaking Abstracts at the World Muscle...
2025-10-13 16:03
1120
The 138th Canton Fair is Set to Open in Guangzhou on October 15
GUANGZHOU, China, Oct. 13, 2025 /PRNewswire/ -- The 138th China Import and Export Fair (Canton Fair) is set to open inGuangzhou from October 15 to November 4, divided into three phases. The fair will maintain its 24-hour online presence to offer global buyers continuous access to Chinese supplier...
2025-10-13 14:42
1971
Lundbeck's bexicaserin receives Breakthrough Therapy Designation in China for the treatment of seizures in severe rare epilepsies
* Accelerated pathway underscores urgent need for innovative solutions for patients with devastating, childhood-onset epilepsies * Novel 5HT2C mechanism designed to reduce drug-resistant seizures in children and adults living with Developmental Epileptic Encephalopathies (DEEs) and improve qu...
2025-10-13 14:26
1024
ISTH marks World Thrombosis Day with urgent global call to action
Thrombosis is the underlying cause of 1 in 4 deaths worldwide each year. The
campaign calls for crucial awareness and prevention.
CHARLOTTE, N.C., Oct. 13, 2025 /PRNewswire/ -- The International Society on
Thrombosis and Haemostasis
2025-10-13 14:00
720
Singclean Anti-adhesion Technology With Professor Osama Shawki Shines at FIGO
CAPE TOWN, South Africa, Oct. 13, 2025 /PRNewswire/ -- Singclean Medical, in partnership with Kayan Al-Seha Medical (KSM) and ProfessorOsama Shawki, successfully made its debut at the FIGO World Congress of Gynecology and Obstetrics 2025, held from October 5–9 at the Cape Town International Conv...
2025-10-13 13:00
1282
Everest Medicines Announces NMPA Approval of IND Application for Tumor-Associated Antigen Cancer Vaccine EVM14
* EVM14 becomes Everest Medicines' internally developed therapeutic mRNA cancer vaccine to receive IND approvals from bothChina's National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA). * EVM14, an off-the-shelf therapeutic mRNA cancer vaccine, is devel...
2025-10-13 08:47
1331
Week's Top Stories
Most Reposted
Nine Years of Impact: JULO Disburses USD 1.7 Billion in Digital Financing Across Indonesia
[Picked up by 297 media titles]
2025-12-23 14:23
ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly
[Picked up by 278 media titles]
2025-12-26 12:55ACEN completes transition to 100% renewable energy
[Picked up by 270 media titles]
2025-12-29 18:53CYFIRMA's 2025 Impact Recap Showcases DeCYFIR, Preemptive External Threat Landscape Management Platform, Delivering Measurable Global Defense Against Emerging Threats
[Picked up by 262 media titles]
2025-12-29 09:00
ChinaAMC launches Depository Receipts of two Chinese flagship ETFs in Thai exchange
[Picked up by 259 media titles]
2025-12-29 14:27Most Read
GreenTree Hospitality Group Ltd. Reports Third Quarter of 2025 Financial Results
2025-12-23 22:30
3805
Highway Holdings Plans to Acquire 51% of Regent-Feinbau Adermann GmbH
2025-12-23 20:00
3546
